Empagliflozin shows efficacy in curbing A1C rates in diabetes

05/8/2013 | Medscape (free registration)

Empagliflozin monotherapy showed A1C benefits comparable with metformin treatment in type 2 diabetes patients, a study presented at the American Association of Clinical Endocrinologists annual meeting indicated. Researchers also found patients who used empagliflozin as an add-on to metformin therapy attained better fasting plasma glucose levels and greater reductions in body weight at 90 weeks than those who took sitagliptin as an add-on.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ